Show simple item record

Sweat testing infants detected by cystic fibrosis newborn screening

dc.contributor.authorParad, Richard B.
dc.contributor.authorComeau, Anne Marie
dc.contributor.authorDorkin, Henry L.
dc.contributor.authorDovey, Mark
dc.contributor.authorGerstle, Robert
dc.contributor.authorMartin, Thomas
dc.contributor.authorO'Sullivan, Brian P.
dc.date2022-08-11T08:10:14.000
dc.date.accessioned2022-08-23T17:00:46Z
dc.date.available2022-08-23T17:00:46Z
dc.date.issued2005-09-06
dc.date.submitted2012-01-11
dc.identifier.citationJ Pediatr. 2005 Sep;147(3 Suppl):S69-72. <a href="http://dx.doi.org/10.1016/j.jpeds.2005.08.015">Link to article on publisher's site</a>
dc.identifier.issn0022-3476 (Linking)
dc.identifier.doi10.1016/j.jpeds.2005.08.015
dc.identifier.pmid16202787
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43863
dc.description.abstractOBJECTIVE: Describe and define limitations of early pilocarpine iontophoresis (sweat testing) for cystic fibrosis (CF) newborn screening (NBS). STUDY DESIGN: Population-based results from follow-up of CF NBS-positive newborns. RESULTS: Insufficient quantity of sweat is more likely if the sweat test is done too early, but testing is generally successful after 2 weeks of age. Sweat chloride levels drop over the first weeks of life. CF carriers have higher sweat chloride concentrations than non-carriers. CONCLUSIONS: Sweat testing can be performed effectively after 2 weeks of age for CF NBS-positive newborns. Earlier testing has a higher risk of insufficient sweat for completing testing.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=16202787&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.jpeds.2005.08.015
dc.subjectAge Factors
dc.subjectAlgorithms
dc.subjectChlorides
dc.subjectCystic Fibrosis
dc.subjectDNA Mutational Analysis
dc.subjectDecision Trees
dc.subjectEarly Diagnosis
dc.subjectFalse Negative Reactions
dc.subjectFalse Positive Reactions
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectInfant, Newborn
dc.subjectIontophoresis
dc.subjectLinear Models
dc.subjectMassachusetts
dc.subjectMuscarinic Agonists
dc.subjectNeonatal Screening
dc.subjectPatient Selection
dc.subjectPilocarpine
dc.subjectReference Values
dc.subjectReferral and Consultation
dc.subjectRisk Factors
dc.subjectSweat
dc.subjectAllergy and Immunology
dc.subjectPediatrics
dc.subjectRespiratory Tract Diseases
dc.titleSweat testing infants detected by cystic fibrosis newborn screening
dc.typeJournal Article
dc.source.journaltitleThe Journal of pediatrics
dc.source.volume147
dc.source.issue3 Suppl
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_pulmonary/9
dc.identifier.contextkey2441369
html.description.abstract<p>OBJECTIVE: Describe and define limitations of early pilocarpine iontophoresis (sweat testing) for cystic fibrosis (CF) newborn screening (NBS).</p> <p>STUDY DESIGN: Population-based results from follow-up of CF NBS-positive newborns.</p> <p>RESULTS: Insufficient quantity of sweat is more likely if the sweat test is done too early, but testing is generally successful after 2 weeks of age. Sweat chloride levels drop over the first weeks of life. CF carriers have higher sweat chloride concentrations than non-carriers.</p> <p>CONCLUSIONS: Sweat testing can be performed effectively after 2 weeks of age for CF NBS-positive newborns. Earlier testing has a higher risk of insufficient sweat for completing testing.</p>
dc.identifier.submissionpathpeds_pulmonary/9
dc.contributor.departmentNew England Newborn Screening Program
dc.contributor.departmentDepartment of Pediatrics
dc.source.pagesS69-72


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record